{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:54Z","timestamp":1792854234013,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To develop a proposal for giant cell arteritis remission criteria in order to implement a treat-to-target\u00a0algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A task force consisting of 10 rheumatologists, 3 cardiologists, 1 nephrologist, and 1 cardiac surgeon was established in the Large-vessel Vasculitis Group of the Japanese Research Committee of the Ministry of Health, Labour and Welfare for Intractable\u00a0Vasculitis to conduct a Delphi survey of remission criteria for giant cell arteritis. The survey was circulated among the members over four reiterations with four face-to-face meetings. Items with a mean score of \u22654 were extracted as items for defining remission criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>An initial literature review yielded a total of 117 candidate items for disease activity domains and treatment\/comorbidity domains of remission criteria, of which 35 were extracted as disease activity domains (systematic symptoms, signs and symptoms of cranial and large-vessel area, inflammatory markers, and imaging findings). For the treatment\/comorbidity domain, \u22645\u2009mg\/day of prednisolone 1 year after starting glucocorticoids was extracted. The definition of achievement of remission was the disappearance of active disease in the disease activity domain, normalization of inflammatory markers, and \u22645\u2009mg\/day of prednisolone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We developed proposals for remission criteria to guide the implementation of a treat-to-target\u00a0algorithm for giant cell arteritis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road046","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:49:45Z","timestamp":1684979385000},"page":"568-575","source":"Crossref","is-referenced-by-count":4,"title":["Establishing clinical remission criteria for\u00a0giant cell arteritis: Results of\u00a0a Delphi exercise carried out by an expert panel of\u00a0the Japan Research Committee of\u00a0the Ministry of\u00a0Health, Labour, and\u00a0Welfare for\u00a0Intractable\u00a0Vasculitis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"first","affiliation":[{"name":"Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo, Japan"},{"name":"Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine , Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences , Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"First Department of Physiology, Kawasaki Medical School , Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tanemoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Kawasaki Medical School , Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuka","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine , Suita, Japan"},{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute , Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine , Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Nagafuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine , Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine , Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Faculty of Medical Sciences, Kyushu University , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Clinical Research, Innovation and Education Center, Tohoku University Hospital , Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute , Suita, Japan"},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"2024032817140730700_R1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3899\/jrheum.110275","article-title":"Development of\u00a0outcome measures for\u00a0large-vessel vasculitis for\u00a0use in\u00a0clinical trials: opportunities, challenges, and\u00a0research agenda","volume":"38","author":"Direskeneli","year":"2011","journal-title":"J Rheumatol"},{"key":"2024032817140730700_R2","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3899\/jrheum.161467","article-title":"Development of\u00a0a core set of\u00a0outcome measures for\u00a0large-vessel vasculitis: report from OMERACT 2016","volume":"44","author":"Sreih","year":"2017","journal-title":"J Rheumatol"},{"key":"2024032817140730700_R3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of\u00a0tocilizumab in\u00a0giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2024032817140730700_R4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of\u00a0abatacept (CTLA-4Ig) for\u00a0the treatment of\u00a0giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024032817140730700_R5","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for\u00a0steroid sparing in\u00a0patients with giant-cell arteritis: results of\u00a0a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024032817140730700_R6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and\u00a0safety of\u00a0mavrilimumab in\u00a0giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024032817140730700_R7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of\u00a0the EULAR recommendations for\u00a0the management of\u00a0large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024032817140730700_R8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.41165","article-title":"Diagnostic assessment strategies and\u00a0disease subsets in\u00a0giant cell arteritis: data from an international observational cohort","volume":"72","author":"Gribbons","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024032817140730700_R9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.011","article-title":"Different patterns and\u00a0specific outcomes of\u00a0large-vessel involvements in\u00a0giant cell arteritis","volume":"103","author":"de Boysson","year":"2019","journal-title":"J Autoimmun"},{"key":"2024032817140730700_R10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.semarthrit.2018.05.002","article-title":"Arterial lesions in\u00a0giant cell arteritis: a longitudinal study","volume":"48","author":"Kermani","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024032817140730700_R11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"(18) F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in\u00a0a prospective, longitudinal cohort of\u00a0patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024032817140730700_R12","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","article-title":"Resolution of\u00a0vascular inflammation in\u00a0patients with new-onset giant cell arteritis: data from the RIGA study","volume":"60","author":"Schonau","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024032817140730700_R13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001417","article-title":"Efficacy and\u00a0safety of\u00a0tocilizumab in\u00a0giant cell arteritis: a single centre NHS experience using imaging (ultrasound and\u00a0PET-CT) as a diagnostic and\u00a0monitoring tool","volume":"6","author":"Sebastian","year":"2020","journal-title":"RMD Open"},{"key":"2024032817140730700_R14","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02171-6","article-title":"Associated factors of\u00a0poor treatment outcomes in\u00a0patients with giant cell arteritis: clinical implication of\u00a0large vessel lesions","volume":"22","author":"Sugihara","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024032817140730700_R15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/mr\/roab081","article-title":"Establishing clinical remission criteria and\u00a0the framework of\u00a0a treat-to-target\u00a0algorithm for\u00a0Takayasu arteritis: results of\u00a0a Delphi exercise carried out by an expert panel of\u00a0the Japan Research Committee of\u00a0the Ministry of\u00a0Health, Labour and\u00a0Welfare for\u00a0Intractable\u00a0Vasculitis","volume":"32","author":"Sugihara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024032817140730700_R16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 guideline on\u00a0management of\u00a0vasculitis syndrome \u2013 digest version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ J"},{"key":"2024032817140730700_R17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for\u00a0maintenance of\u00a0glucocorticosteroid-induced remission of\u00a0giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024032817140730700_R18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of\u00a0etanercept in\u00a0patients with giant cell arteritis and\u00a0corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024032817140730700_R19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for\u00a0induction and\u00a0maintenance of\u00a0remission in\u00a0giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"2024032817140730700_R20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of\u00a0giant-cell arteritis with methotrexate and\u00a0prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"2024032817140730700_R21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of\u00a0adjuvant methotrexate treatment for\u00a0giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2024032817140730700_R22","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of\u00a0giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024032817140730700_R23","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3899\/jrheum.141144","article-title":"Update on\u00a0outcome measure development for\u00a0large vessel vasculitis: report from OMERACT 12","volume":"42","author":"Aydin","year":"2015","journal-title":"J Rheumatol"},{"key":"2024032817140730700_R24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3899\/jrheum.181072","article-title":"Update on\u00a0outcome measure development in\u00a0large-vessel vasculitis: report from OMERACT 2018","volume":"46","author":"Aydin","year":"2019","journal-title":"J Rheumatol"},{"key":"2024032817140730700_R25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/kex397","article-title":"Evaluation of\u00a0damage in\u00a0giant cell arteritis","volume":"57","author":"Kermani","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024032817140730700_R26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.151063","article-title":"The Birmingham Vasculitis Activity Score as a measure of\u00a0disease activity in\u00a0patients with giant cell arteritis","volume":"43","author":"Kermani","year":"2016","journal-title":"J Rheumatol"},{"key":"2024032817140730700_R27","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac122","article-title":"Association between the patterns of\u00a0large-vessel lesions and\u00a0treatment outcomes in\u00a0patients with large-vessel giant cell arteritis","author":"Sugihara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024032817140730700_R28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of\u00a0Rheumatology\/Vasculitis Foundation guideline for\u00a0the management of\u00a0giant cell arteritis and\u00a0Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024032817140730700_R29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and\u00a0acute-phase reactant levels at giant cell arteritis flare in\u00a0a randomized trial of\u00a0tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024032817140730700_R30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","article-title":"Predictors of\u00a0relapse and\u00a0treatment outcomes in\u00a0biopsy-proven giant cell arteritis: a retrospective cohort study","volume":"55","author":"Labarca","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2024032817140730700_R31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in\u00a0giant cell arteritis: results of\u00a0a randomized controlled trial of\u00a0tocilizumab in\u00a0giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024032817140730700_R32","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of\u00a018F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on\u00a0vascular inflammation in\u00a0giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road046\/50516040\/road046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/568\/57109166\/road046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/3\/568\/57109166\/road046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:54:18Z","timestamp":1711648458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/3\/568\/7178022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,24]]},"published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road046","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,5,24]]}}}